A new study shows that increasing the number of cycles with temozolomide for glioblastoma patients brings no additional benefits and increases the toxicity of the treatment
The trial, the results of which have been published in been published in the journal "Neuro Oncology", was led by the researcher and medical oncologist Carme Balaña and included a large group of professionals from the ICO.